Physicians' Academy for Cardiovascular Education

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

Statin-associated muscle symptoms: real or nocebo effect?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - Mar. 22, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

The ORBITA trial: is PCI beneficial in stable angina patients?

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. William Boden, Boston, MA, USA

Considerations on antithrombotic treatment of VTE and AF patients

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Mutated bone marrow stem cells may link aging, cancer and atherosclerosis

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USA

Dyslipidemia in diabetes patients

10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Rudolfstiftung Hospital, Vienna, Austria

Anti-inflammatory therapy in the prevention of cardiovascular disease

10' education - Nov. 16, 2017 - Prof. Peter Libby, USA

Appropriate use of NOACs: What is the state of the art for 2018?

15' education - Feb. 20, 2018 - Prof. John Eikelboom, McMaster University, Hamilton, Ontario, Canada

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK

Practical guidance on NOACs and safety: How to deal with challenging situations in AF

15' education - Feb. 20, 2018 - Prof. John Eikelboom - Hamilton, ON, Canada

Results of ODYSSEY OUTCOMES and FOURIER trials complement each other

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA

Messages from the ODYSSEY OUTCOMES trial

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK

CV health scores are declining and CVD rates are increasing in the US

Literature - May 24, 2018 - Enserro DM, et al. - J Am Heart Assoc. 2018
CV health scores have decreased over the past 20 years, resulting in an increased risk of developing subclinical disease and incident CVD, as well as all-cause mortality.

CV health scores have decreased over the past 20 years, resulting in an increased risk of developing subclinical disease and incident CVD, as well as all-cause mortality.

Yogurt consumption before an unhealthy meal reduces postprandial inflammation

Literature - May 24, 2018 - Pei R, et al. - J Nutr 2018

Pre-meal yogurt consumption improved acute postprandial dysfunction after a high-fat, high-calorie meal in obese and non-obese women.

Factor Xa inhibitor shows lack of efficacy with increased bleeding in patients with embolic stroke of undetermined source

Literature - May 23, 2018 - Hart RG, et al. - N Engl J Med 2018

Rivaroxaban therapy is not beneficial for the prevention of stroke recurrence and associated with a higher risk of bleeding compared to aspirin in patients with embolic stroke of undetermined source.

SGLT2 inhibitor improves clinical outcomes in T2DM patients with a history of coronary artery bypass graft surgery

Literature - May 23, 2018 - Verma S, et al. - Diabetologia 2018
In type 2 diabetic patients with a history of CABG, empagliflozin reduced significantly CV- and all-cause mortality, HF hospitalization, and incident or worsening nephropathy compared with placebo.

In type 2 diabetic patients with a history of CABG, empagliflozin reduced significantly CV- and all-cause mortality, HF hospitalization, and incident or worsening nephropathy compared with placebo.

Cardiovascular Inflammation Reduction Trial (CIRT) stopped early

News - May 22, 2018

The CIRT trial evaluating low-dose methotrexate to lower CV risk has been stopped early, not based on any substantive safety concerns.

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany
After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

VBWG at ACC 2018 After lack of sham-controlled trials, the SPYRAL program has started to test the efficacy of renal denervation in patients with uncontrolled hypertension. Two pilot studies with a sham controlled group in patients without and with medications are nearly finished.

Healthy food intake and high cardiorespiratory fitness both important to slow progression of CAC

Literature - May 16, 2018 - Gripeteg L et al. - Am J Cardiol 2018

Healthy food intake was associated with having no coronary artery calcium, and in combination with higher cardiorespiratory fitness, it was also associated with lower CAC levels.

EC approves PCSK9 inhibitor for patients with established atherosclerotic CVD

News - May 16, 2018

The European Commission (EC) has approved the use of evolocumab in patients with established atherosclerotic CVD (MI, stroke, PAD) to reduce CV risk.

How internet searches may lead to statin intolerance

News - May 16, 2018

A Google-driven nocebo effect may underlie statin intolerance, as countries with many websites on statin side-effects showed a higher prevalence of statin intolerance.

GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease

Literature - May 16, 2018 - Verma S, et al. - Circulation 2018
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Simple malnutrition scores predict mortality in HF

Literature - May 16, 2018 - Sze S, et al. - J Am Coll Cardiol HF 2018
Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.

Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.

Folic acid treatment reduces the risk of stroke in hypertensive patients

Literature - May 16, 2018 - Kong X et al. - J Am Coll Cardiol 2018
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.